Lightpoint Medical announced Wednesday that its SENSEI robotic gamma probe received the CE mark for intra-operative detection of sentinel lymph nodes. The company said the approval makes SENSEI the first robotic gamma probe to be commercially available to hospitals in Europe.
CEO David Tuch remarked that securing the CE mark “underscores our commitment to meet surgeons’ needs for miniaturised cancer detection tools as robotic platform technologies grow to dominate surgical practice.”
According to Lightpoint, SENSEI is also designed to detect cancer metastasis through the lymphatic system. Specifically, the technology locates single-photon emission computed tomography (SPECT) radioligands, such as 99mTc-nanocolloid for sentinel lymph node detection, or cancer-targeted drugs for metastasis detection such as 99mTc-PSMA in prostate cancer surgery. The company indicated that its technology is also applicable across a wide range of major cancer types, including lung, colorectal, stomach, gynaecological and prostate.
Lightpoint added that the device was registered with the FDA in September 2020.